The stock of niche financial software company Vertex ( VERX 4.13%) didn't get a very good start to the trading week at all.
The potential approval of Vertex’s IgAN therapy povetacicept in 2026 comes amid launch headwinds for the company’s non-opioid ...
KING OF PRUSSIA, Pa., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ: VERX) (“Vertex” or the “Company”), a leading global provider of indirect tax solutions, today announced financial results ...
Oh no! It’s happening again. I’m beginning to appreciate a design that I earlier just couldn’t wrap my head around. New shapes, forms and proportions that initially looked awkward are slowly starting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback